Publication Name	World Journal of Clinical Oncology
Manuscript ID	59742
Country	Spain

Received	2020-09-27 17:27
Peer-Review Started	2020-09-27 17:27
To Make the First Decision
Return for Revision	2021-01-07 06:20
Revised	2021-01-07 15:24
Second Decision	2021-01-21 03:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-01-26 18:31
Articles in Press	2021-01-26 18:31
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-01-29 23:27
Typeset the Manuscript	2021-02-01 05:32
Publish the Manuscript Online	2021-02-22 12:47

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Metastatic hormone-sensitive prostate cancer: How should it be treated?
Manuscript Source	Invited Manuscript
All Author List	Fernando López-Campos, Carmen González-San Segundo, Antonio José Conde-Moreno and Felipe Couñago
Funding Agency and Grant Number
Corresponding Author	Felipe Couñago, MD, PhD, Professor, Department of Radiation Oncology, Hospital Universitario Quirón Salud Madrid, Hospital La Luz, Universidad Europea de Madrid (UEM), Calle Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Madrid 28223, Spain. fcounago@gmail.com
Key Words	Metastatic hormone-sensitive prostate cancer; Androgen-receptor signaling inhibitors; Abiraterone acetate; Enzalutamide; Apalutamide; Docetaxel
Core Tip	Due to advances in the treatment of metastatic hormone-sensitive prostate cancer in recent years, multiple options are now available. The emergence of androgen receptor inhibitors provides patients with an alternative to chemotherapy. Given the increasingly important role of these novel treatments, a comprehensive review of the available data is needed. In addition, there are several unresolved questions and controversies surrounding these treatments, which can only be resolved by in-depth analysis and consensus among the specialists who treat these patients.
Publish Date	2021-02-22 12:47
Citation	López-Campos F, González-San Segundo C, Conde-Moreno AJ, Couñago F. Metastatic hormone-sensitive prostate cancer: How should it be treated? World J Clin Oncol 2021; 12(2): 43-49
URL	https://www.wjgnet.com/2218-4333/full/v12/i2/43.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i2.43

Full Article (PDF)	WJCO-12-43.pdf
Full Article (Word)	WJCO-12-43.docx
Manuscript File	59742-Review-FilipodiaCL.doc
Answering Reviewers	59742-Answering reviewers.pdf
Audio Core Tip	59742-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	59742-Conflict-of-interest statement.pdf
Copyright License Agreement	59742-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	59742-Language certificate.pdf
Peer-review Report	59742-Peer-review(s).pdf
Scientific Misconduct Check	59742-Bing-Wang JL-1.jpg
Scientific Misconduct Check	59742-Scientific misconduct check.pdf
Scientific Editor Work List	59742-Scientific editor work list.pdf